DXCM vs VIR · P/E 63, rev $2.50B vs rev $238.9M
DexCom Inc (DXCM) versus Vir Biotechnology Inc (VIR) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Vir Biotechnology Inc (VIR) is a biotechnology company listed on NASDAQ.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported VIR revenue for 2026-06-30 was $238.9M. Net income was -$45.6M. VIR currently screens at market cap $1.45B.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. VIR currently screens at market cap $1.45B.
Not investment advice. Open the DXCM and VIR stock pages for the full models.
Not investment advice.